array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(51) "Amgen to launch Eylea biosimilar after court ruling" ["snippet_en"]=> string(260) "Amgen will launch Pavblu, its biosimilar to Regeneron's Eylea, after a US Court of Appeals decision denied Regeneron's request to halt the launch. The ruling allows Amgen to expand access to its treatment despite Regeneron's ongoing patent infringement claims." ["url"]=> string(84) "https://www.aiche.org/news/industry/amgen-launch-eylea-biosimilar-after-court-ruling" ["image_url"]=> NULL ["source"]=> string(9) "aiche.org" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(5) { [0]=> string(10) "Litigation" [1]=> string(18) "Expansion & Growth" [2]=> string(14) "Product Launch" [3]=> string(8) "Verdicts" [4]=> string(5) "Legal" } } [1]=> array(7) { ["title_en"]=> string(89) "Campaign Highlights the Role of Caregivers in Eye Health Awareness for Retinal Conditions" ["snippet_en"]=> string(142) "This fall, Prevent Blindness and Regeneron are expanding their eye health awareness initiative, 'The Gr8 Eye Movement,' to emphasize the cruci" ["url"]=> string(115) "https://eyewire.news/news/campaign-highlights-the-role-of-caregivers-in-eye-health-awareness-for-retinal-conditions" ["image_url"]=> NULL ["source"]=> string(12) "eyewire.news" ["publication_date"]=> string(10) "2024-10-29" ["categories"]=> array(1) { [0]=> string(18) "Expansion & Growth" } } [2]=> array(7) { ["title_en"]=> string(50) "Regeneron to invest $1.8bn at Tarrytown, NY campus" ["snippet_en"]=> string(124) "Regeneron will invest $1.8 billion over six years to expand its manufacturing, support, and research facilities in New York." ["url"]=> string(99) "https://www.bioprocessintl.com/facilities-capacity/regeneron-to-invest-1-8bn-at-tarrytown-ny-campus" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2ad9e98c-88e1-4f54-9f40-08786f5bce54" ["source"]=> string(18) "bioprocessintl.com" ["publication_date"]=> string(10) "2024-10-12" ["categories"]=> array(3) { [0]=> string(18) "Expansion & Growth" [1]=> string(20) "Business Development" [2]=> string(18) "General Investment" } } [3]=> array(7) { ["title_en"]=> string(91) "Regeneron Pharmaceuticals continues to expand Capital Region footprint — Down to Business" ["snippet_en"]=> string(175) "With its purchase of the former million-square-foot Quad plant in Saratoga Springs, Regeneron Pharmaceuticals has easily doubled its commercial holdings in the Capital Region." ["url"]=> string(114) "https://dailygazette.com/news/regeneron-pharmaceuticals-saratoga/article_32eb7cd2-80e9-11ef-a541-53005d524094.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e5fad13b-aba5-4682-bdc4-0f6bffc008f8" ["source"]=> string(16) "dailygazette.com" ["publication_date"]=> string(10) "2024-10-02" ["categories"]=> array(3) { [0]=> string(18) "Expansion & Growth" [1]=> string(20) "Business Development" [2]=> string(25) "Business Model Resilience" } } [4]=> array(7) { ["title_en"]=> string(63) "Regeneron Pharmaceuticals Set for Growth with Dupixent Approval" ["snippet_en"]=> string(162) "Regeneron Pharmaceuticals is poised for future growth after receiving Dupixent's approval for COPD treatment, reflecting investor confidence and market potential." ["url"]=> string(100) "https://investorshangout.com/regeneron-pharmaceuticals-set-for-growth-with-dupixent-approval-45155-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d958b088-b490-4840-bcd7-ce42c2c9679c" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-09-28" ["categories"]=> array(2) { [0]=> string(18) "Expansion & Growth" [1]=> string(15) "Market Movement" } } [5]=> array(7) { ["title_en"]=> string(63) "Regeneron Pharmaceuticals: A Deep Dive Into Bear's Perspective!" ["snippet_en"]=> string(148) "Regeneron Pharmaceuticals reported substantial growth in its second quarter of 2024, with a 12% increase in total revenues to $3.55 billion. This..." ["url"]=> string(111) "https://www.smartkarma.com/insights/regeneron-pharmaceuticals-a-deep-dive-into-bear-s-perspective-major-drivers" ["image_url"]=> string(78) "https://images.businessradar.com/articles/53cf88b9-2549-429f-ad76-2adc2786a0be" ["source"]=> string(14) "smartkarma.com" ["publication_date"]=> string(10) "2024-08-12" ["categories"]=> array(3) { [0]=> string(18) "Expansion & Growth" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Quarterly/Annual Figures" } } [6]=> array(7) { ["title_en"]=> string(85) "Regeneron Pharmaceuticals Buys 235,000 SF Life Sciences Facility in Suffern, New York" ["snippet_en"]=> string(296) "SUFFERN, N.Y. — Regeneron Pharmaceuticals (NASDAQ: REGN) has purchased Avon Innovation Center, a 235,000-square-foot life sciences facility in Suffern, located just across the New York-New Jersey border. The seller, pharmaceutical company Avon, will be vacating the building in the near future." ["url"]=> string(113) "https://rebusinessonline.com/regeneron-pharmaceuticals-buys-235000-sf-life-sciences-facility-in-suffern-new-york/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ec4a11f8-f4e5-4408-b88f-5ea0d8de6613" ["source"]=> string(20) "rebusinessonline.com" ["publication_date"]=> string(10) "2024-02-28" ["categories"]=> array(3) { [0]=> string(18) "Expansion & Growth" [1]=> string(11) "Acquisition" [2]=> string(7) "Opening" } } [7]=> array(7) { ["title_en"]=> string(55) "Preliminary rendering off proposed Regeneron expansion." ["snippet_en"]=> string(55) "Preliminary rendering off proposed Regeneron expansion." ["url"]=> string(176) "https://westfaironline.com/combined/westchester-ida-supports-2-2b-worth-of-projects-in-2023-4b-over-two-years/attachment/preliminary-rendering-off-proposed-regeneron-expansion/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c8a04296-b0c9-4f28-b69d-4411ac95e4bf" ["source"]=> string(18) "westfaironline.com" ["publication_date"]=> string(10) "2024-02-11" ["categories"]=> array(1) { [0]=> string(18) "Expansion & Growth" } } [8]=> array(7) { ["title_en"]=> string(58) "Shoreham-Wading River High School opens new fitness center" ["snippet_en"]=> string(232) "Abraham Lincoln’s famous quote, “The best way to predict the future is to create it,” now embellishes the wall of Shoreham-Wading River High School’s new state-of-the-art Health and Wellness Center, which is officially open." ["url"]=> string(118) "https://riverheadnewsreview.timesreview.com/2023/12/118493/shoreham-wading-river-high-school-opens-new-fitness-center/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/86450a69-2f5b-4bd7-925b-102a30c82748" ["source"]=> string(15) "timesreview.com" ["publication_date"]=> string(10) "2023-12-20" ["categories"]=> array(4) { [0]=> string(18) "Expansion & Growth" [1]=> string(7) "Opening" [2]=> string(17) "Academic Research" [3]=> string(11) "Competition" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc